Last kr399.00 DKK
Change Today -2.50 / -0.62%
Volume 2.7K
AMBUB On Other Exchanges
Symbol
Exchange
Copenhagen
As of 4:29 AM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

ambu a/s-b (AMBUB) Snapshot

Open
kr403.00
Previous Close
kr367.50
Day High
kr405.00
Day Low
kr396.00
52 Week High
09/19/14 - kr440.00
52 Week Low
10/30/13 - kr241.00
Market Cap
4.8B
Average Volume 10 Days
11.9K
EPS TTM
kr7.93
Shares Outstanding
10.2M
EX-Date
12/13/13
P/E TM
50.3x
Dividend
kr1.25
Dividend Yield
0.31%
Current Stock Chart for AMBU A/S-B (AMBUB)

Related News

No related news articles were found.

ambu a/s-b (AMBUB) Related Businessweek News

No Related Businessweek News Found

ambu a/s-b (AMBUB) Details

Ambu A/S provides healthcare solutions in anesthesia, patient monitoring and diagnostics, and emergency care fields worldwide. The company offers anesthesia products, including laryngeal masks, ventilation bags, face masks for artificial ventilation, scopes for visualization, anesthesia tubes, and pumps for palliative care; patient monitoring and diagnostics products, such as single-use electrodes for neurological and cardiological examinations, and tubes and needles; emergency care products comprising neck collars, manikins, and other equipment for first-aid training; conductive adhesive gels for use in the production of skin-contacting biomedical electrodes; and single-use videoscopes. The company serves hospitals, clinics, rescue services and sleep laboratories, aid organizations, and the armed forces. It sells and exports its products through direct sales and distributors. The company was founded in 1937 and is headquartered in Ballerup, Denmark.

2,350 Employees
Last Reported Date: 08/20/14
Founded in 1937

ambu a/s-b (AMBUB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ambu a/s-b (AMBUB) Key Developments

Ambu A/S Reports Unaudited Group Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014; Reaffirms Earnings Guidance for the Fiscal 2014

Ambu A/S reported unaudited group earnings results for the third quarter and nine months ended June 30, 2014. For the quarter, the company reported revenue of DKK 397 million compared to revenue of DKK 378 million for the same period a year ago. Operating profit (EBIT) before special items was DKK 55 million compared to DKK 39 million last year. Operating profit (EBIT) was DKK 55 million compared to DKK 25 million last year. Profit before tax (PBT) was DKK 45 million compared to DKK 11 million last year. Net profit was DKK 33 million or DKK 2.73 per diluted share compared to DKK 6 million or DKK 0.56 per basic and diluted share last year. Net interest-bearing debt was DKK 784 million compared to DKK 767 million last year. Return on equity was 14% compared to 9% last year. ROIC after tax including goodwill was 11% compared to 10% last year. Profit before interest, tax, depreciation and amortization (EBITDA), before special items was DKK 78 million compared to DKK 62 million last year. Cash flows from operating activities were DKK 53 million compared to DKK 27 million last year. Free cash flows before acquisitions were DKK 28 million compared to DKK 10 million last year. For the nine months, the company reported revenue of DKK 1,142 million compared to revenue of DKK 982 million for the same period a year ago. Operating profit (EBIT) before special items was DKK 118 million compared to DKK 102 million last year. Operating profit (EBIT) was DKK 118 million compared to DKK 55 million last year. Profit before tax (PBT) was DKK 90 million compared to DKK 33 million last year. Net profit was DKK 66 million or DKK 5.47 per diluted share compared to DKK 20 million or DKK 1.76 per diluted share last year. Cash flows from operating activities were DKK 110 million compared to DKK 65 million last year. Purchase of non-current assets was DKK 53 million compared to DKK 47 million last year. Free cash flows after acquisitions were DKK 51 million compared to DKK 679 million last year. Return on equity was 14% compared to 9% last year. ROIC after tax including goodwill was 11% compared to 10% last year. Profit before interest, tax, depreciation and amortization (EBITDA), before special items was DKK 181 million compared to DKK 154 million last year. Free cash flows before acquisitions were DKK 57 million compared to DKK 24 million last year. The outlook for fiscal 2014 is unchanged compared to the outlook announced in the annual report for fiscal 2013 on 14 November 2013. For the fiscal 2014, the company expects revenue is to be DKK 1.6 billion. Organic growth is to b approximately 6% to 7% against the previously announced approximately 5% to 7%. EBIT margin is to be approximately 13% against the previously announced approximately 12% to 14%. Free cash flows are to be approximately DKK 100 million to DKK 120 million. NIBD/EBITDA is to be approximately 2.5. The outlook is based on an average USD/DKK exchange rate of 550.

Ambu A/S, Q3 2014 Earnings Call, Aug 20, 2014

Ambu A/S, Q3 2014 Earnings Call, Aug 20, 2014

Ambu A/S Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 08:00 AM

Ambu A/S Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 08:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Lars Marcher, Chief Executive Officer, President and Member of Executive Board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMBUB:DC kr399.00 DKK -2.50

AMBUB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Repro-Med Systems Inc $0.35 USD 0.00
View Industry Companies
 

Industry Analysis

AMBUB

Industry Average

Valuation AMBUB Industry Range
Price/Earnings 49.1x
Price/Sales 2.9x
Price/Book 6.3x
Price/Cash Flow 40.8x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMBU A/S-B, please visit www.ambu.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.